Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

This study demonstrates that patients with diabetes taking thiazolidinediones have higher proportions of distal upper and lower limb fractures than those not taking the drug. : To determine if ...

Background: The introduction of several new therapeutic agents for the treatment of type 2 diabetes mellitus has led to significant challenges for providers in deciding which agent to select during ...

Compared with nonuse, GLP-1RA and thiazolidinedione combination therapy reduced risks for all-cause and cardiovascular mortality in type 2 diabetes. The combination of a glucagon-like peptide 1 ...

Thiazolidinedione use was associated with an increased risk for fracture among adults with type 2 diabetes, especially women after 4 years. Thiazolidinediones increase the risk for fracture among ...

Thiazolidinediones activate peroxisome proliferative activated receptor γ, which increases insulin sensitivity and makes these agents an effective treatment for diabetes. Animal studies have indicated ...

To study whether T33, a new synthesized non-thiazolidinedione (TZD) peroxisome proliferator-activated receptor (PPAR) γ/α dual agonist has an antidiabetic effect on ob/ob mice. Ob/ob mice were treated ...

The introduction of several new therapeutic agents for the treatment of type 2 diabetes mellitus over the past several years has led to significant challenges for healthcare professionals. Therapeutic ...